Medically reviewed by David Ozeri, MD Psoriatic arthritis (PsA) develops in four stages: the preclinical stage, where those ...
A recent study on psoriatic arthritis care revealed that patients and clinicians agree on key aspects of disease management ...
Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.
Explore the gap between patient and clinician perspectives in psoriatic arthritis care. Learn how priorities differ and why ...
The NHS says psoriatic arthritis is a long-term condition that causes joint pain, swelling and stiffness. Medicines can help treat the symptoms. Some people with the skin condition psoriasis may ...